Bailard’s Immunovant IMVT Stock Holding History

Bailard’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,300	Closed	-$265K	–	774
2023 Q4	$265K	Hold	6,300	–	–	0.01%	575
2023 Q3	$242K	Buy	+6,300	New	+$142K	0.01%	600
2023 Q2	–	Sell	-12,200	Closed	-$189K	–	735
2023 Q1	$189K	Hold	12,200	–	–	0.01%	661
2022 Q4	$217K	Buy	+12,200	New	+$154K	0.01%	631

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Bailard's IMVT Position: Q1 2024 in Review

Bailard sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 6,300 shares — an estimated $265K sold.

Bailard first reported a position in IMVT in Q4 2022 and held it in 4 quarters. The position peaked at $265K in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

Bailard reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
Bailard sold 6,300 Immunovant shares in Q1 2024, an estimated $265K.
Bailard first reported a position in Immunovant in Q4 2022 and held it in 4 quarters.
Bailard's Immunovant position peaked at $265K in Q4 2023.
209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Bailard's 13F filing for Q1 2024, filed 8 May 2024.